Results 271 to 280 of about 288,727 (306)
Some of the next articles are maybe not open access.
Inhibitors of the insulin receptor tyrosine kinase
Pharmacology & Therapeutics, 1994Insulin is a polypeptide hormone consisting of 51 amino acids. Insulin promotes a variety of anabolic enzymatic pathways and inhibits many catabolic enzymatic pathways involved in energy storage, as well as in synthesis of structural tissue proteins.
P R, Srinivas, G, Grunberger
openaire +2 more sources
Arrhythmic Complications of Tyrosine Kinase Inhibitors
Future Cardiology, 2015Division of Cardiovascular Medicine, University of South Florida, Morsani College of Medicine, 2 Tampa General Circle, Tampa, FL 33606, USA Department of Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA *Author for correspondence: mfradley@health.usf ...
Michael G, Fradley +1 more
openaire +2 more sources
Tyrosine kinase inhibitor induced pancreatitis
Journal of Oncology Pharmacy Practice, 2012Sorafenib and sunitinib are oral tyrosine kinase inhibitors, commonly used in the treatment of metastatic renal cell carcinoma. Known adverse events associated with tyrosine kinase inhibitors include hypertension and palmarplantar erythrodysesthesia. We report two cases of acute pancreatitis associated with tyrosine kinase inhibitors.
Adrienne, Sevin +2 more
openaire +2 more sources
2016
Breast cancer is the most common cancer in women worldwide. Although various subgroups are defined according to the expression of hormones and ErbB family receptors, it is well known that this disease is more heterogeneous than its classification system suggests.
Burcu Cakar, Erdem Göker
openaire +1 more source
Breast cancer is the most common cancer in women worldwide. Although various subgroups are defined according to the expression of hormones and ErbB family receptors, it is well known that this disease is more heterogeneous than its classification system suggests.
Burcu Cakar, Erdem Göker
openaire +1 more source
Seminars in cancer biology, 1993
Tyrosine kinases are associated with the cytoplasmic domains of growth factor receptors as well as oncoproteins and many have the potential to cause transformation if mutated or hyperexpressed. Tyrosine kinases therefore represent an excellent target for the development of cancer drugs.
P, Workman, V G, Brunton, D J, Robins
openaire +1 more source
Tyrosine kinases are associated with the cytoplasmic domains of growth factor receptors as well as oncoproteins and many have the potential to cause transformation if mutated or hyperexpressed. Tyrosine kinases therefore represent an excellent target for the development of cancer drugs.
P, Workman, V G, Brunton, D J, Robins
openaire +1 more source
Tyrosine Kinase Inhibitors in Pediatric Malignancies
Cancer Investigation, 2007Tyrosine kinase inhibitors have been used to treat adult cancers for over a decade. Since the discovery of imatinib mesylate (STI-571, Gleevec; Novartis), tyrosine kinase inhibitors have ushered in a new age of targeted therapy. Although the United States Food and Drug Administration has approved several kinase inhibitors for use in adult cancers ...
Jeffrey M, Skolnik, Peter C, Adamson
openaire +2 more sources
Tyrosine kinase inhibitors and immunotherapy combinations in renal cell carcinoma
Therapeutic Advances in Medical Oncology, 2020Elie Rassy +2 more
exaly